Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30 Salt Lake City, Utah

Inc. to Participate in the Lytham

Fall 2025 Investor Conference on

Lake City, Utah - September 30, 2025 - Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"),

a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that

it will be participating in a webcast presentation and hosting one-on-one meetings with institutional investors at the Lytham Partners

Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Company presentation will take place today at 4:15 p.m. ET, and can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/

or directly at https://app.webinar.net/bwLr50QqD7v. The webcast will also be available for replay following the event. The slide

deck used in the presentation can be found on https://ir.co-dx.com/.

will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham

Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.

Co-Diagnostics, Inc.:

Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.

The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA).

The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject

to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.